Areas where scientific evidence is lacking or incomplete.
No Phase III human clinical trials under Western regulatory frameworks (FDA, EMA) exist for Semax, Selank, Dihexa or P21 in ADHD populations. Existing human evidence is predominantly from adjacent indications (stroke, dementia, healthy-volunteer cognition) and Russian-language case-series literature.
Implications: Every efficacy claim for these peptides in ADHD is an inference from adjacent indications or preclinical models. Effect magnitude, response predictors, non-responder rates, and population safety signals are all unknown for ADHD specifically. The protocol operates on mechanistic plausibility plus adjacent-indication evidence, not primary-indication evidence.
The regenerative framework's core claim is that compounds like Dihexa produce semi-permanent structural reconnection rather than transient neurochemical effect. Longitudinal human evidence for persistence years after cessation does not exist.
Implications: Whether users require booster cycles indefinitely or whether the structural reconnections persist is undetermined. The cycling discipline recommended across the literature is a risk-management heuristic, not a validated long-term protocol. Claims of semi-permanence should be read as hypotheses, not as characterised properties.
Chronic multi-year use of synthetic neuropeptides in humans is essentially unstudied. Dihexa's HGF/c-Met activation is the most concrete concern - theoretical oncogenic risk from sustained growth-factor pathway stimulation that current data cannot exclude.
Implications: Safe-for-a-cycle and safe-over-years are distinct questions, and available literature addresses only the first. Cancer surveillance for users of HGF-activating compounds is a clinical necessity inferred from mechanism, not from empirical human data. The safety margin in elderly or oncologically vulnerable populations is particularly uncharacterised.
There is effectively no human data for Semax, Selank, Dihexa or P21 in pediatric ADHD populations. Cerebrolysin has pediatric literature in different indications (perinatal hypoxic-ischaemic encephalopathy, developmental delay) but not ADHD.
Implications: The pediatric gap is severe enough that this protocol treats it as a hard contraindication. Extending adult peptide dosing to children is not supported by data and risks effects on developmental neurobiology - particularly synaptic pruning, dopaminergic system maturation, and endocrine development - that adult literature cannot predict.
Current Semax, Selank and P21 dose ranges derive from Russian clinical literature in adjacent indications and from biohacker self-report. No ADHD-specific dose-response curves exist in peer-reviewed literature. Semax guidance spans 100 mcg to 1 mg; the ADHD-specific therapeutic threshold is unestablished.
Implications: The protocol's Safe-Default column is conservative by construction - positioned below biohacker experimental ranges and within the lower half of clinical-indication dosing. Even conservative dosing is an informed estimate rather than a titration against ADHD-specific endpoints. Users should interpret recommended ranges as starting points with individual titration, not as validated therapeutic doses.
For users concurrently on methylphenidate or amphetamine-class ADHD medications, pharmacodynamic interaction data with Semax, Selank or Dihexa is absent. Mechanistic concerns exist - Semax modulates dopamine release, which overlaps with stimulant mechanism - but formal interaction studies do not.
Implications: Risks in the combination include over-stimulation, cardiovascular stress, serotonergic imbalance and hypokinetic rebound. The prudent approach is to introduce peptide cycles only on a stable stimulant baseline (6+ weeks), stagger timing, and monitor sleep and blood pressure closely. Empirical caution is not a substitute for interaction data.
The regulatory landscape is inconsistent - Semax and Selank are listed as Vital and Essential Drugs in Russia but FDA Category 2 prohibited-for-compounding in the US. Cerebrolysin is simultaneously described as 'FDA-approved' and 'not registered for US use' in different clinical sources. Practical sourcing routes for Western users are cross-border supply chains with significant purity and endotoxin risk.
Implications: Users navigating access have no clear legal pharmacy route in most Western jurisdictions. The risk profile of the supply chain - contamination, mislabelling, dose variance - is a material part of the overall risk calculus, separate from the peptides themselves. Third-party lot-specific COA is the minimum mitigation; absence of COA is a reason not to proceed.
Dihexa's proposed HGF/c-Met mechanism and its 'ten million times more potent than BDNF' claim derive from literature with data-integrity concerns, and the Dihexa-derived human therapeutic fosgonimeton (ATH-1017) failed Phase 2/3 in Alzheimer's.
Implications: When the mechanistic basis for a compound's use is contested and its human translation has failed, rational dose optimisation, combination design and adverse-effect prediction all become unreliable. Continued citation of HGF/c-Met in secondary sources reflects citation lag more than independent validation. Dihexa use operates on a preclinical evidence base whose interpretation is genuinely unsettled.
Expert disagreements and competing evidence.
Cerebrolysin is FDA-approved in the USA as a novel treatment of Alzheimer's in adults.
Clinical practice summaries and promotional literature citing Alzheimer's indications.
The FDA has not registered Cerebrolysin for use in the United States; it is not approved for human therapeutic use in the US or EU.
FDA drug registry; independent regulatory summaries noting non-approval in US and EU.
Verdict Note
Multiple regulatory sources confirm Cerebrolysin is not FDA-registered for US use. The 'FDA-approved' framing appears in clinical sources promoting the compound but is not supported by the FDA drug registry. The operational position: Cerebrolysin is not a US-approved drug, is available through importation or specialised clinic routes, and is not FDA-approved for ADHD under any framework.
The FDA banned 17 peptide treatments, prohibiting compounding pharmacies from selling them.
Headlines and commentary describing the action as a ban on peptide treatments.
The FDA issued guidance restricting compounding of certain peptides via Category 2 Bulk Drug Substance classification, citing safety risks - this is regulatory guidance, not a substance ban.
FDA Category 2 determinations citing significant safety risks and insufficient human data.
Verdict Note
The FDA action is formally a Category 2 classification that prohibits compounding for human use - not a blanket substance ban. The substances themselves are not illegal; their compounded preparation for human use is prohibited. The 'ban' framing is headline-optimised rather than accurate. The practical effect for US users is nonetheless significant: legal pharmacy-compounded access is closed.
Semax has an exceptional safety profile with minimal adverse effects and no significant organ toxicity.
Russian institutional clinical publications, multi-indication case series.
Semax may pose immunogenicity risk; the FDA lacks sufficient information to determine whether the drug would cause harm in US populations.
FDA Category 2 Bulk Drug Substance documentation for Semax.
Verdict Note
Both statements are partly true. Russian clinical case-series evidence is real and shows favourable in-setting safety across multi-decade use. The FDA position is also real - insufficient data by US pharmacovigilance standards plus immunogenicity concerns that may not have been surfaced by Russian-population case series. The honest synthesis is favourable case-series evidence in Russian clinical use, insufficient to meet FDA thresholds for US population approval.
Cerebrolysin is generally safe and well-tolerated, including in pediatric populations for indications such as developmental delay.
Clinical trial literature in stroke, dementia and pediatric developmental indications.
A systematic review reported an increase in serious non-fatal adverse events with Cerebrolysin including acute coronary syndrome, heart failure and pulmonary embolism.
Systematic review reporting ACS, heart failure and PE signals with Cerebrolysin in susceptible populations.
Verdict Note
Both statements reflect real populations. Cerebrolysin's overall safety profile in standard clinical indications is favourable. The serious AE signal appears concentrated in susceptible populations with pre-existing cardiac or thromboembolic risk. The operational read is that Cerebrolysin is specialist-administration territory, risk-stratified by patient history - which is precisely why this ADHD protocol treats Cerebrolysin as clinical-only rather than home-protocol material.
Cerebrolysin is derived from pig and cow brains.
Secondary source commentary.
Cerebrolysin is derived strictly from purified porcine (pig) brain proteins.
Manufacturer product documentation and independent regulatory summaries.
Verdict Note
The weight of manufacturer and independent regulatory sources specifies porcine-only origin. The pig-and-cow framing appears in some secondary sources but is not supported by manufacturer product documentation. Operational implication for users with religious, dietary or prion-concern considerations: porcine-only sourcing is the documented position.
The mechanism of action of Semax is unknown; it might interact with melanocortin receptors or enkephalinase enzymes.
Pharmacology review literature citing melanocortin and enkephalinase pathway candidates.
Semax works by upregulation of Brain-Derived Neurotrophic Factor (BDNF) and modulation of dopaminergic, serotonergic and GABAergic systems.
Clinical handbooks, sports medicine summaries, Russian pharmacology literature describing BDNF/TrkB and neurotransmitter system modulation.
Verdict Note
The BDNF/TrkB effect is measured and reproducible across multiple studies. Whether that effect is the primary mechanism of Semax's cognitive action, an important secondary effect, or a downstream consequence of melanocortin or enkephalinase activity is not settled. Clinical sources describing the mechanism with certainty overstate what the mechanistic literature supports. The honest position is that BDNF upregulation is real but the full mechanistic picture remains candidate-level.
P21 has suitable pharmacokinetics for oral administration.
Preclinical stability studies showing 90% gastric-fluid stability at 30 minutes and 100% intestinal-fluid stability at 2 hours.
P21 dosing tables list only subcutaneous and intranasal routes, omitting oral dosing.
P21 dosing table entries in clinical summaries omit oral routes.
Verdict Note
The same source that describes P21 as orally viable provides a dosing table that omits oral routes. The discrepancy may reflect a gap between preclinical pharmacokinetic data (supporting oral viability) and clinical dosing practice (subcutaneous and intranasal as characterised routes). This protocol defaults to subcutaneous as the conservative characterised route, treating oral viability as preclinical-supported but not clinically-established.
Omega-3 fatty acids are among the best supplements for managing ADHD, improving attention and reducing hyperactivity.
Smaller clinical trials and clinical summary literature showing attention and hyperactivity improvements.
A large systematic review found no clinically significant effect on ADHD core symptoms when rated by parents or teachers.
Systematic review aggregating multiple trials with standardised outcome measures.
Verdict Note
Both statements reflect real data. Smaller studies and some clinical summaries show attention and hyperactivity benefits; larger systematic reviews with standardised outcome measures show no clinically significant core-symptom effect. The likely synthesis is subgroup-specific benefit (low-baseline omega-3 status, specific behavioural profiles) against a weak overall population-level effect. Omega-3 belongs in an ADHD nutritional foundation; it should not be sold as a primary treatment.